Managing Deviations with Control and Confidence

In a pharmaceutical environment, deviations are not a sign of failure. They are a fact of life. For MHRA and HPRA, the real question is whether deviations are recognised quickly, investigated robustly, and used to strengthen the quality system – or simply written up to get the file closed. Their GMP/GDP guidance and inspection reports make it clear that deviation management is one of the sharpest indicators of whether a system is genuinely in control.

Deviations as a Window into the Quality System

Every deviation reveals how the system behaves under real conditions. A warehouse temperature excursion tests the reality of storage and monitoring; a documentation error exposes how workable procedures and training actually are; and a distribution mix-up shows the quality of interfaces with 3PLs and contract sites.

HPRA explicitly defines deviations as non-conformances with GDP, legislation, or in-house procedures and requires a written process for identifying, documenting, investigating, and closing them – including root cause and CAPA. Documentation must start as soon as a potential deviation is recognised, and not when someone later decides it is serious enough. Further reading: HPRA Guide to GDP.

For GDP, MHRA's own inspection data make the same point: weak deviation systems are a recurrent major deficiency. Published GDP deficiency reports highlight deviations being signed off before CAPAs are implemented at the 3PL, cold-chain temperature deviations not followed by CAPAs, and non-contemporaneous deviation records that undermine data integrity. These findings reinforce that timely, honest deviation recording and investigation are core expectations of GDP for wholesale distributors. Further reading: MHRA GDP Deficiency Data.

MHRA's guidance on unexpected deviations under Annex 16 reinforces the same principle for manufacturing: deviations affecting certified or to-be-certified batches must be fully understood, risk-assessed, and justified before a QP can certify – and they must be genuinely unexpected, not routine work-arounds. Further reading: MHRA on handling unexpected deviations.

What "Good" Looks Like for MHRA and HPRA

Across MHRA inspectorate blogs and HPRA guidance, four themes are consistent.

1. Visibility

People at all levels recognise what a deviation is and log it in real time. Management receives meaningful trend data – not just a raw count – and uses it to steer resources, risks, and priorities.

2. Structure

There is a defined path from event to decision: the event is identified and recorded; immediate containment follows; an impact and risk assessment is carried out covering product, patient, and regulatory considerations; evidence-based root-cause analysis is performed; CAPA is assigned with owners and deadlines; an effectiveness check leads to closure; and findings feed into trending and management review.

3. Proportionality

Both MHRA and HPRA expect formal use of quality risk management (ICH Q9). Effort is scaled to potential impact: minor issues receive simple documented assessments, while higher-risk issues demand structured investigation and escalation.

4. Learning

Outputs from deviations must feed into training, SOP and process redesign, supplier oversight, and strategic decisions. Repeated similar deviations should be taken as evidence that the system is not learning and that CAPA is ineffective. Further reading: MHRA – A fresh look at investigations in the GMDP environment.

Where Systems Typically Fail

MHRA deficiency data are transparent about frequent failures.

• Late or reluctant recording – investigations raised long after the event, often reconstructed from memory.
• Superficial investigations – narrative stories with little or no supporting data; impact on batches or patients not clearly assessed; risk assessments written to justify a pre-chosen outcome.
• "Human error" as the default root cause – repeated use of "operator did not follow SOP" with retraining as the only CAPA, while workload, system design, and supervision are ignored. MHRA has explicitly warned that this is not acceptable root-cause practice.
• Weak CAPA linkage and trending – actions recorded on deviation forms but not integrated into the CAPA system; the same issues recurring; no evidence that management reviews deviation trends or checks CAPA effectiveness.

These are exactly the patterns that lead to major and critical findings during GMP/GDP inspections.

Key Takeaway

Inspectors are not impressed by thick deviation files. They are impressed by timely recording, honest root-cause analysis, realistic CAPAs, and visible learning over time. Appropriately used, deviations are among the most substantial evidence that an organisation understands its risks and is genuinely in control of its supply chain.